Migraines linked to interferon-β treatment of multiple sclerosis

Alex Khromov, Miriam Segal, Jeffrey Nissinoff, Avital Fast

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Migraine headache is now emerging as a previously under-recognized side effect of interferon-β, the most commonly used therapy for relapsing multiple sclerosis (MS). We describe an MS patient who developed migraine headaches, which followed a specific pattern coincident with interferon-β administration. The frequency and severity of these migraines escalated and seemed to culminate in an MS exacerbation. Since initiation of migraine prophylaxis with daily amitriptyline, our patient reported a significant decrease in the frequency and severity of her migraines on interferon. It has been postulated that migraine headaches may trigger MS relapse. If so, migraine prophylaxis in MS patients, especially those treated with interferon-β, is of paramount importance. Migraine headaches can be a significant source of disability. Identifying and treating migraines in MS patients serves to enhance their function and reduce disability.

Original languageEnglish (US)
Pages (from-to)644-647
Number of pages4
JournalAmerican Journal of Physical Medicine and Rehabilitation
Volume84
Issue number8
DOIs
StatePublished - Aug 2005

Fingerprint

Migraine Disorders
Interferons
Multiple Sclerosis
Therapeutics
Amitriptyline
Recurrence

Keywords

  • Interferon-β
  • Migraine
  • Multiple Sclerosis

ASJC Scopus subject areas

  • Rehabilitation
  • Health Professions(all)
  • Orthopedics and Sports Medicine
  • Physical Therapy, Sports Therapy and Rehabilitation

Cite this

Migraines linked to interferon-β treatment of multiple sclerosis. / Khromov, Alex; Segal, Miriam; Nissinoff, Jeffrey; Fast, Avital.

In: American Journal of Physical Medicine and Rehabilitation, Vol. 84, No. 8, 08.2005, p. 644-647.

Research output: Contribution to journalArticle

@article{4abf614298f541afa5564ec5a38188cf,
title = "Migraines linked to interferon-β treatment of multiple sclerosis",
abstract = "Migraine headache is now emerging as a previously under-recognized side effect of interferon-β, the most commonly used therapy for relapsing multiple sclerosis (MS). We describe an MS patient who developed migraine headaches, which followed a specific pattern coincident with interferon-β administration. The frequency and severity of these migraines escalated and seemed to culminate in an MS exacerbation. Since initiation of migraine prophylaxis with daily amitriptyline, our patient reported a significant decrease in the frequency and severity of her migraines on interferon. It has been postulated that migraine headaches may trigger MS relapse. If so, migraine prophylaxis in MS patients, especially those treated with interferon-β, is of paramount importance. Migraine headaches can be a significant source of disability. Identifying and treating migraines in MS patients serves to enhance their function and reduce disability.",
keywords = "Interferon-β, Migraine, Multiple Sclerosis",
author = "Alex Khromov and Miriam Segal and Jeffrey Nissinoff and Avital Fast",
year = "2005",
month = "8",
doi = "10.1097/01.phm.0000171012.86932.10",
language = "English (US)",
volume = "84",
pages = "644--647",
journal = "American Journal of Physical Medicine and Rehabilitation",
issn = "0894-9115",
publisher = "Lippincott Williams and Wilkins",
number = "8",

}

TY - JOUR

T1 - Migraines linked to interferon-β treatment of multiple sclerosis

AU - Khromov, Alex

AU - Segal, Miriam

AU - Nissinoff, Jeffrey

AU - Fast, Avital

PY - 2005/8

Y1 - 2005/8

N2 - Migraine headache is now emerging as a previously under-recognized side effect of interferon-β, the most commonly used therapy for relapsing multiple sclerosis (MS). We describe an MS patient who developed migraine headaches, which followed a specific pattern coincident with interferon-β administration. The frequency and severity of these migraines escalated and seemed to culminate in an MS exacerbation. Since initiation of migraine prophylaxis with daily amitriptyline, our patient reported a significant decrease in the frequency and severity of her migraines on interferon. It has been postulated that migraine headaches may trigger MS relapse. If so, migraine prophylaxis in MS patients, especially those treated with interferon-β, is of paramount importance. Migraine headaches can be a significant source of disability. Identifying and treating migraines in MS patients serves to enhance their function and reduce disability.

AB - Migraine headache is now emerging as a previously under-recognized side effect of interferon-β, the most commonly used therapy for relapsing multiple sclerosis (MS). We describe an MS patient who developed migraine headaches, which followed a specific pattern coincident with interferon-β administration. The frequency and severity of these migraines escalated and seemed to culminate in an MS exacerbation. Since initiation of migraine prophylaxis with daily amitriptyline, our patient reported a significant decrease in the frequency and severity of her migraines on interferon. It has been postulated that migraine headaches may trigger MS relapse. If so, migraine prophylaxis in MS patients, especially those treated with interferon-β, is of paramount importance. Migraine headaches can be a significant source of disability. Identifying and treating migraines in MS patients serves to enhance their function and reduce disability.

KW - Interferon-β

KW - Migraine

KW - Multiple Sclerosis

UR - http://www.scopus.com/inward/record.url?scp=22644446283&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=22644446283&partnerID=8YFLogxK

U2 - 10.1097/01.phm.0000171012.86932.10

DO - 10.1097/01.phm.0000171012.86932.10

M3 - Article

C2 - 16034235

AN - SCOPUS:22644446283

VL - 84

SP - 644

EP - 647

JO - American Journal of Physical Medicine and Rehabilitation

JF - American Journal of Physical Medicine and Rehabilitation

SN - 0894-9115

IS - 8

ER -